Standard-dose PPIs QD

DRUG2 trials

Sponsors

Ironwood Pharmaceuticals, Inc.

Conditions

Gastroesophageal Reflux Disease (GERD)

Phase 3

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

TerminatedNCT03561090

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2018-06-20End: 2020-11-03Updated: 2021-08-19

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

CompletedNCT03561883

Ironwood Pharmaceuticals, Inc.Gastroesophageal Reflux Disease (GERD)

Start: 2018-09-06End: 2020-11-06Updated: 2021-08-18